Glenmark Pharmaceuticals Limited has released its investor presentation for the second quarter of the fiscal year 2027. The report details consolidated revenue of Rs. 42,473 million, reflecting a ~20% like-for-like YoY growth. Key regional highlights include strong performance in India and Emerging Markets. The presentation also outlines advancements in its global innovative portfolio, including key product updates and clinical trial progress.
Glenmark Pharmaceuticals Investor Presentation Q2 FY27
Glenmark Pharmaceuticals Limited has issued an investor presentation for the second quarter of the fiscal year 2027 (Q2 FY27), highlighting its financial performance and strategic progress. The presentation was submitted to the stock exchanges on November 5, 2026.
Financial Performance Summary
The company reported a Consolidated Revenue of Rs. 42,473 million for Q2 FY27. This represents a ~20% year-on-year growth on a like-for-like basis. The profitability metrics for the quarter include a consolidated R&D investment of Rs. 3,449 million, EBITDA of Rs. 8,638 million (with an EBITDA margin of 20.3%), and an Adjusted PAT (Profit After Tax) of Rs. 4,852 million (with an Adj. PAT margin of 11.4%).
Regional Business Highlights
Key regional performance indicators for Q2 FY27 include:
- India: Business growth of ~14%.
- North America: Core business growth of ~31%, benefiting from multiple launches and recovery.
- Europe: Business growth of 6.2%, demonstrating resilient performance amidst challenging market conditions.
- Emerging Markets: Business growth of 33.2%, driven by strong execution and portfolio expansion.
Global Innovative Portfolio Update
The presentation also provided updates on Glenmark’s global innovative pipeline:
- RYALTRIS®: Commercialized in 58 markets, with launches in Brazil in Q2 FY27 and 10 more markets expected.
- WINLEVI®: Launched in several EU markets and achieved formulary status covering ~40% of the UK market potential.
- QİNHAYO™ (ENVAFOLIMAB): Marketing authorization applications filed in 24 countries, with early access programs initiated in nine markets.
- TRASTUZUMAB REZETECAN: Submitted marketing authorization applications in two markets and initiated Phase 3 clinical trials in India.
- AUMOLERTINIB: Marketing authorization applications filed in 13 markets, with the first commercial launch anticipated during H2 FY27.
IGI – Key Updates
Updates from the IGI (Integrated Genomics and Immunology) division include:
- ISB 2001/ABBV-2001: Phase 1 study progress with over 170 subjects dosed. Updated clinical data presented at ASH 2026.
- ISB 2301: A first-in-class multispecific immune cell activator for solid tumors, with an IND submission planned by the end of CY26.
- ISB 2302 and ISB 2501: In early preclinical development.
- ISB 880/LAD191: Phase II HS study expected to read out in 2027.
- ISB 830 (telazorlimab) and ISB 830-X8/STAR-0310: Licensing rights for STAR-0310 are returning to IGI, with strategic pathways being evaluated.
The presentation underscores Glenmark’s focus on sustained growth, strategic product launches, and advancing its innovative pipeline.
Source: BSE
